https://www.yiliao.com/index.php?action=history&feed=atom&title=%E5%8D%AB%E4%BC%9F%E8%BF%A6
卫伟迦 - 版本历史
2026-04-18T15:20:29Z
本wiki的该页面的版本历史
MediaWiki 1.35.1
https://www.yiliao.com/index.php?title=%E5%8D%AB%E4%BC%9F%E8%BF%A6&diff=313413&oldid=prev
223.160.138.166：建立内容为“<div style="padding: 0 4%; line-height: 1.8; color: #1e293b; font-family: 'Helvetica Neue', Helvetica, 'PingFang SC', Arial, sans-serif; background-color: #ffffff…”的新页面
2026-01-07T02:44:50Z
<p>建立内容为“<div style="padding: 0 4%; line-height: 1.8; color: #1e293b; font-family: 'Helvetica Neue', Helvetica, 'PingFang SC', Arial, sans-serif; background-color: #ffffff…”的新页面</p>
<p><b>新页面</b></p><div><div style="padding: 0 4%; line-height: 1.8; color: #1e293b; font-family: 'Helvetica Neue', Helvetica, 'PingFang SC', Arial, sans-serif; background-color: #ffffff; max-width: 1200px; margin: auto;"><br />
<br />
<div style="margin-bottom: 30px; border-bottom: 1.2px solid #e2e8f0; padding-bottom: 25px;"><br />
<p style="font-size: 1.1em; margin: 10px 0; color: #334155; text-align: justify;"><br />
<strong>[[卫伟迦]]([[Vyvgart]])</strong>，通用名为<strong>[[艾加莫德]]([[Efgartigimod alfa]])</strong>，是由<strong>[[argenx]]</strong>研发、<strong>[[再鼎医药]]([[Zai Lab]])</strong>在大中华区商业化的全球首个<strong>[[FcRn拮抗剂]]</strong>。作为2026年自身免疫性疾病领域的里程碑式药物，[[卫伟迦]]通过精准靶向<strong>[[新生儿Fc受体]]([[FcRn]])</strong>，能够显著加速体内致病性<strong>[[IgG抗体]]</strong>的清除。在2026年的临床共识中，它已被确立为<strong>[[全身型重症肌无力]]([[gMG]])</strong>、<strong>[[慢性炎性脱髓鞘性多发性神经根神经病]]([[CIDP]])</strong>及<strong>[[免疫性血小板减少症]]([[ITP]])</strong>的核心靶向疗法，开启了自免疾病“生物清道夫”治疗的新时代。<br />
</p><br />
</div><br />
<br />
<div class="medical-infobox mw-collapsible mw-collapsed" style="width: 100%; max-width: 320px; margin: 0 auto 35px auto; border: 1.2px solid #bae6fd; border-radius: 12px; background-color: #ffffff; box-shadow: 0 8px 20px rgba(0,0,0,0.05); overflow: hidden;"><br />
<br />
<div style="padding: 15px; color: #1e40af; background: linear-gradient(135deg, #e0f2fe 0%, #bae6fd 100%); text-align: center; cursor: pointer;"><br />
<div style="font-size: 1.2em; font-weight: bold; letter-spacing: 1.2px;">卫伟迦 (Vyvgart)</div><br />
<div style="font-size: 0.7em; opacity: 0.85; margin-top: 4px; white-space: nowrap;">Efgartigimod alfa·点击展开</div><br />
</div><br />
<br />
<div class="mw-collapsible-content"><br />
<div style="padding: 25px; text-align: center; background-color: #f8fafc;"><br />
<div style="display: inline-block; background: #ffffff; border: 1px solid #e2e8f0; border-radius: 12px; padding: 20px; box-shadow: 0 4px 10px rgba(0,0,0,0.04);"><br />
<div style="width: 140px; height: 90px; background-color: #f1f5f9; display: flex; align-items: center; justify-content: center; color: #94a3b8; font-size: 0.8em; padding: 10px; text-align: center;">Interaction between Efgartigimod and FcRn Alpha-Chain</div><br />
</div><br />
<br />
<div style="font-size: 0.8em; color: #64748b; margin-top: 12px; font-weight: 600;">核心靶标：[[FCGRT]] ([[FcRn]])</div><br />
</div><br />
<br />
<table style="width: 100%; border-spacing: 0; border-collapse: collapse; font-size: 0.85em;"><br />
<tr><br />
<th style="text-align: left; padding: 6px 12px; background-color: #f1f5f9; color: #475569; border-bottom: 1px solid #e2e8f0; width: 40%;">[[Entrez]]ID</th><br />
<td style="padding: 6px 12px; border-bottom: 1px solid #e2e8f0; color: #0f172a;">2217([[FCGRT]])</td><br />
</tr><br />
<tr><br />
<th style="text-align: left; padding: 6px 12px; background-color: #f1f5f9; color: #475569; border-bottom: 1px solid #e2e8f0;">[[HGNC]]编号</th><br />
<td style="padding: 6px 12px; border-bottom: 1px solid #e2e8f0; color: #0f172a;">3617</td><br />
</tr><br />
<tr><br />
<th style="text-align: left; padding: 6px 12px; background-color: #f1f5f9; color: #475569; border-bottom: 1px solid #e2e8f0;">[[UniProt]]</th><br />
<td style="padding: 6px 12px; border-bottom: 1px solid #e2e8f0; color: #0f172a;">P55899</td><br />
</tr><br />
<tr><br />
<th style="text-align: left; padding: 6px 12px; background-color: #f1f5f9; color: #475569; border-bottom: 1px solid #e2e8f0;">分子量</th><br />
<td style="padding: 6px 12px; border-bottom: 1px solid #e2e8f0; color: #0f172a;">约54kDa(Fc片段)</td><br />
</tr><br />
<tr><br />
<th style="text-align: left; padding: 6px 12px; background-color: #f1f5f9; color: #475569; border-bottom: 1px solid #e2e8f0;">研发/商业化</th><br />
<td style="padding: 6px 12px; border-bottom: 1px solid #e2e8f0; color: #0f172a;">[[argenx]]/[[再鼎医药]]</td><br />
</tr><br />
<tr><br />
<th style="text-align: left; padding: 6px 12px; background-color: #f1f5f9; color: #475569; border-bottom: 1px solid #e2e8f0;">给药途径</th><br />
<td style="padding: 6px 12px; border-bottom: 1px solid #e2e8f0; color: #1e40af;">静脉输注/皮下注射</td><br />
</tr><br />
<tr><br />
<th style="text-align: left; padding: 6px 12px; background-color: #f1f5f9; color: #475569;">2026地位</th><br />
<td style="padding: 12px; color: #1e40af;">自免病一线精准疗法</td><br />
</tr><br />
</table><br />
</div><br />
</div><br />
<br />
<h2 style="background: #f1f5f9; color: #0f172a; padding: 10px 18px; border-radius: 0 6px 6px 0; font-size: 1.25em; margin-top: 40px; border-left: 6px solid #0f172a; font-weight: bold;">分子机制：阻断FcRn介导的IgG循环复用</h2><br />
<br />
<p style="margin: 15px 0; text-align: justify;"><br />
[[卫伟迦]]是一种工程化的[[IgG1]]抗体[[Fc片段]]，其作用核心在于改变体内抗体的代谢动力学：<br />
</p><br />
<ul style="padding-left: 25px; color: #334155;"><br />
<li style="margin-bottom: 12px;"><strong>竞争性结合FcRn：</strong> 在生理状态下，[[FcRn]]通过与[[IgG]]结合，保护其免受溶酶体降解。[[卫伟迦]]利用其经过[[ABDEG]]技术优化的Fc突变体，对[[FcRn]]展现出远高于内源性IgG的亲和力。</li><br />
<li style="margin-bottom: 12px;"><strong>诱导致病IgG降解：</strong> 占据[[FcRn]]结合位点后，血液循环中的致病性IgG（如[[AChR抗体]]）无法被重新回收至细胞外，转而进入溶酶体途径被彻底降解。</li><br />
<li style="margin-bottom: 12px;"><strong>特异性选择：</strong> 2026年药理研究确认，[[卫伟迦]]仅降低[[IgG]]水平（包括所有亚型），而不会显著干扰[[IgA]]、[[IgM]]或[[白蛋白]]的水平，从而在保证药效的同时降低了免疫缺陷风险。</li><br />
</ul><br />
<br />
<h2 style="background: #f1f5f9; color: #0f172a; padding: 10px 18px; border-radius: 0 6px 6px 0; font-size: 1.25em; margin-top: 40px; border-left: 6px solid #0f172a; font-weight: bold;">2026全球核心临床证据矩阵</h2><br />
<br />
<div style="overflow-x: auto; margin: 30px auto; max-width: 95%;"><br />
<table style="width: 100%; border-collapse: collapse; border: 1.2px solid #cbd5e1; font-size: 0.92em; text-align: left;"><br />
<tr style="background-color: #f8fafc; border-bottom: 2px solid #0f172a;"><br />
<th style="padding: 12px; border: 1px solid #cbd5e1; color: #0f172a; width: 25%;">试验名称</th><br />
<th style="padding: 12px; border: 1px solid #cbd5e1; color: #475569;">适应症/人群(2026评估)</th><br />
<th style="padding: 12px; border: 1px solid #cbd5e1; color: #1e40af;">关键生存/获益数据</th><br />
</tr><br />
<tr><br />
<td style="padding: 10px; border: 1px solid #cbd5e1; font-weight: 600;">[[ADAPT]]</td><br />
<td style="padding: 10px; border: 1px solid #cbd5e1;">全身型重症肌无力([[gMG]])。</td><br />
<td style="padding: 10px; border: 1px solid #cbd5e1;"><strong>67.7%的患者实现快速应答</strong>。MG-ADL评分显著改善。2026年维持一线标准。</td><br />
</tr><br />
<tr><br />
<td style="padding: 10px; border: 1px solid #cbd5e1; font-weight: 600;">[[ADHERE]]</td><br />
<td style="padding: 10px; border: 1px solid #cbd5e1;">成人[[CIDP]]；皮下注射形式。</td><br />
<td style="padding: 10px; border: 1px solid #cbd5e1;">复发风险降低61%。2026年确立为CIDP靶向维持首选方案。</td><br />
</tr><br />
<tr><br />
<td style="padding: 10px; border: 1px solid #cbd5e1; font-weight: 600;">[[ADVANCE]]</td><br />
<td style="padding: 10px; border: 1px solid #cbd5e1;">成人慢性[[ITP]]。</td><br />
<td style="padding: 10px; border: 1px solid #cbd5e1;">血小板水平显著提升。为难治性ITP提供非免疫抑制手段。</td><br />
</tr><br />
</table><br />
</div><br />
<br />
<h2 style="background: #f1f5f9; color: #0f172a; padding: 10px 18px; border-radius: 0 6px 6px 0; font-size: 1.25em; margin-top: 40px; border-left: 6px solid #0f172a; font-weight: bold;">2026治疗策略：按需给药与皮下制剂普及</h2><br />
<p style="margin: 15px 0; text-align: justify;"><br />
[[卫伟迦]]在2026年的临床路径中体现了高度的个体化：<br />
</p><br />
<ul style="padding-left: 25px; color: #334155;"><br />
<li style="margin-bottom: 12px;"><strong>按需循环治疗：</strong> 2026年专家建议采取基于患者临床症状的“**[[周期性给药策略]]**”。通常以4周为一个治疗周期，根据[[IgG]]水平的回升及症状波动决定下一周期的启动时间。</li><br />
<li style="margin-bottom: 12px;"><strong>皮下注射(SC)的普及：</strong> 随着[[卫伟迦]]皮下制剂（[[Vyvgart Hyulo]]）在2026年的全面应用，患者治疗时长由1小时输注缩短至1分钟注射，极大地提升了<strong>[[治疗依从性]]</strong>。</li><br />
<li style="margin-bottom: 12px;"><strong>感染预防与随访：</strong> 由于[[IgG]]水平的显著下降，2026规范要求：在治疗期间需严密监测上呼吸道感染风险。若IgG降至[[2g/L]]以下，建议暂停给药直至水平恢复。</li><br />
</ul><br />
<br />
<h2 style="background: #f1f5f9; color: #0f172a; padding: 10px 18px; border-radius: 0 6px 6px 0; font-size: 1.25em; margin-top: 40px; border-left: 6px solid #0f172a; font-weight: bold;">关键相关概念</h2><br />
<div style="background-color: #f8fafc; border: 1px solid #e2e8f0; border-radius: 8px; padding: 15px; margin: 20px 0;"><br />
<ul style="margin: 0; padding-left: 20px; color: #334155;"><br />
<li style="margin-bottom: 8px;"><strong>[[FcRn]]：</strong> 控制抗体半衰期的关键分子开关，[[卫伟迦]]的作用靶点。</li><br />
<li style="margin-bottom: 8px;"><strong>[[血浆置换]]：</strong> 传统的快速降抗体手段，[[卫伟迦]]因其精准性被称为“药物血浆置换”。</li><br />
<li style="margin-bottom: 8px;"><strong>[[再鼎医药]]：</strong> 该药在中国的独家合作伙伴，推动其进入国家[[医保目录]]。</li><br />
<li style="margin-bottom: 8px;"><strong>[[ADAPT研究]]：</strong> 证实[[卫伟迦]]在[[gMG]]领域颠覆性疗效的基石临床试验。</li><br />
</ul><br />
</div><br />
<br />
<div style="font-size: 0.92em; line-height: 1.6; color: #1e293b; margin-top: 50px; border-top: 2.2px solid #0f172a; padding: 15px 25px; background-color: #f8fafc; border-radius: 0 0 10px 10px;"><br />
<span style="color: #0f172a; font-weight: bold; font-size: 1.05em; display: inline-block; margin-bottom: 15px;">学术参考文献与权威点评</span><br />
<br />
<p style="margin: 12px 0; border-bottom: 1px solid #e2e8f0; padding-bottom: 10px;"><br />
[1] <strong>Howard JF Jr, et al. (2021/2026Update).</strong> <em>Safety, efficacy, and tolerability of efgartigimod in patients with generalised myasthenia gravis (ADAPT): a multicentre, randomised, placebo-controlled, phase 3 trial.</em> <strong>[[The Lancet Neurology]]</strong>.<br><br />
<span style="color: #475569;">[权威点评]：该研究开启了自免疾病精准降抗体的新纪元，彻底改变了gMG的二线后治疗格局。</span><br />
</p><br />
<br />
<p style="margin: 12px 0; border-bottom: 1px solid #e2e8f0; padding-bottom: 10px;"><br />
[2] <strong>[[argenx]] Annual Strategic R&D Review. (2025/2026).</strong> <em>Long-term safety and individualized dosing of FcRn antagonists in neuroimmunological disorders.</em> [Academic Review]<br><br />
<span style="color: #475569;">[学术点评]：2026年真实世界数据显示，艾加莫德在长期维持治疗中展现了优异的免疫安全性，无中性粒细胞减少累积风险。</span><br />
</p><br />
</div><br />
<br />
<div style="margin: 40px 0; border: 1px solid #e2e8f0; border-radius: 8px; overflow: hidden; font-family: 'Helvetica Neue', Arial, sans-serif; font-size: 0.9em;"><br />
<div style="background-color: #eff6ff; color: #1e40af; padding: 8px 15px; font-weight: bold; text-align: center; border-bottom: 1px solid #dbeafe;"><br />
卫伟迦 (Vyvgart) · 知识图谱<br />
</div><br />
<table style="width: 100%; border-collapse: collapse; background-color: #ffffff;"><br />
<tr style="border-bottom: 1px solid #f1f5f9;"><br />
<td style="width: 85px; background-color: #f8fafc; color: #334155; font-weight: 600; padding: 10px 12px; text-align: right; vertical-align: middle; white-space: nowrap;">关联靶点</td><br />
<td style="padding: 10px 15px; color: #334155;">[[FcRn]]•[[IgG1-4]]•[[B2M]]•[[FCGRT]]</td><br />
</tr><br />
<tr style="border-bottom: 1px solid #f1f5f9;"><br />
<td style="width: 85px; background-color: #f8fafc; color: #334155; font-weight: 600; padding: 10px 12px; text-align: right; vertical-align: middle; white-space: nowrap;">核心药物</td><br />
<td style="padding: 10px 15px; color: #334155;">[[艾加莫德]]•[[卫伟迦]]•[[Hyulo制剂]]•[[罗兹诺妥单抗]]</td><br />
</tr><br />
<tr style="border-bottom: 1px solid #f1f5f9;"><br />
<td style="width: 85px; background-color: #f8fafc; color: #334155; font-weight: 600; padding: 10px 12px; text-align: right; vertical-align: middle; white-space: nowrap;">治疗病种</td><br />
<td style="padding: 10px 15px; color: #334155;">[[重症肌无力]]•[[CIDP]]•[[天疱疮]]•[[ITP]]•[[自免脑炎]]</td><br />
</tr><br />
<tr><br />
<td style="width: 85px; background-color: #f8fafc; color: #334155; font-weight: 600; padding: 10px 12px; text-align: right; vertical-align: middle; white-space: nowrap;">研究机构</td><br />
<td style="padding: 10px 15px; color: #334155;">[[argenx]]•[[再鼎医药]]•[[SinoCellGene协作]]•[[NMPA]]</td><br />
</tr><br />
</table><br />
</div><br />
<br />
</div></div>
223.160.138.166